202 related articles for article (PubMed ID: 19880654)
1. Minireview: physiological and pathological actions of RAS in the ovary.
Fan HY; Richards JS
Mol Endocrinol; 2010 Feb; 24(2):286-98. PubMed ID: 19880654
[TBL] [Abstract][Full Text] [Related]
2. Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis.
Richards JS; Fan HY; Liu Z; Tsoi M; Laguë MN; Boyer A; Boerboom D
Oncogene; 2012 Mar; 31(12):1504-20. PubMed ID: 21860425
[TBL] [Abstract][Full Text] [Related]
3. Consequences of RAS and MAPK activation in the ovary: the good, the bad and the ugly.
Fan HY; Liu Z; Mullany LK; Richards JS
Mol Cell Endocrinol; 2012 Jun; 356(1-2):74-9. PubMed ID: 22197887
[TBL] [Abstract][Full Text] [Related]
4. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells.
Fan HY; Liu Z; Paquet M; Wang J; Lydon JP; DeMayo FJ; Richards JS
Cancer Res; 2009 Aug; 69(16):6463-72. PubMed ID: 19679546
[TBL] [Abstract][Full Text] [Related]
5. Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicle development and ovulation.
Fan HY; Shimada M; Liu Z; Cahill N; Noma N; Wu Y; Gossen J; Richards JS
Development; 2008 Jun; 135(12):2127-37. PubMed ID: 18506027
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2008 Apr; 27(2):151-60. PubMed ID: 18317228
[TBL] [Abstract][Full Text] [Related]
7. Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS
Kun EHS; Tsang YTM; Lin S; Pan S; Medapalli T; Malpica A; Richards JS; Gershenson DM; Wong KK
Sci Rep; 2020 Nov; 10(1):20678. PubMed ID: 33244099
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the KRAS gene in ovarian tumors.
Dobrzycka B; Terlikowski SJ; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(2):221-4. PubMed ID: 19995707
[TBL] [Abstract][Full Text] [Related]
9. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.
Kurman RJ; Visvanathan K; Roden R; Wu TC; Shih IeM
Am J Obstet Gynecol; 2008 Apr; 198(4):351-6. PubMed ID: 18395030
[TBL] [Abstract][Full Text] [Related]
10. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
11. Consequences of elevated luteinizing hormone on diverse physiological systems: use of the LHbetaCTP transgenic mouse as a model of ovarian hyperstimulation-induced pathophysiology.
Mann RJ; Keri RA; Nilson JH
Recent Prog Horm Res; 2003; 58():343-75. PubMed ID: 12795427
[TBL] [Abstract][Full Text] [Related]
12. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
Zhang L; Ma T; Brozick J; Babalola K; Budiu R; Tseng G; Vlad AM
Oncogene; 2016 Sep; 35(38):5010-20. PubMed ID: 26973247
[TBL] [Abstract][Full Text] [Related]
13. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
[TBL] [Abstract][Full Text] [Related]
14. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
16. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
17. Zebrafish rhabdomyosarcoma reflects the developmental stage of oncogene expression during myogenesis.
Storer NY; White RM; Uong A; Price E; Nielsen GP; Langenau DM; Zon LI
Development; 2013 Jul; 140(14):3040-50. PubMed ID: 23821038
[TBL] [Abstract][Full Text] [Related]
18. Human pancreatic duct epithelial cell model for KRAS transformation.
Radulovich N; Qian JY; Tsao MS
Methods Enzymol; 2008; 439():1-13. PubMed ID: 18374152
[TBL] [Abstract][Full Text] [Related]
19. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
20. Oocyte-somatic cell interactions in the human ovary-novel role of bone morphogenetic proteins and growth differentiation factors.
Chang HM; Qiao J; Leung PC
Hum Reprod Update; 2016 Dec; 23(1):1-18. PubMed ID: 27797914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
